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KAJIAN FITOKIMIA DAN ANTIDIABETIK EKSTRAK 
PERESKIA BLEO 
 
ABSTRAK 
 
Kajian ini telah dijalankan bagi mengkaji kesan antidiabetik berserta 
mekanisma tindakan bagi ekstrak daun Pereskia bleo. Pereskia bleo yang berasal 
dari family Cactaceae merupakan salah satu remedi yang sering digunapakai dalam 
perubatan tradisional di Malaysia bagi mengubati beberapa jenis penyakit seperti 
kencing manis, kanser, tekanan darah tinggi, dan beberapa penyakit berkaitan 
dengan penyakit sendi dan keradangan. Bagaimanapun, kajian saintifik masih belum 
mencukupi bagi membuktikan kenyataan ini, terutamanya yang berkaitan dengan 
penyakit kencing manis. Empat jenis ekstrak telah dihasilkan menggunakan cecair 
kimia yang berbeza kepolaran, iaitu petroleum-eter, kloroform, methanol dan air. 
Dalam kajian hipoglisemik dan ujian toleransi glukosa intra-peritoneal (IPGTT), 
kesemua ekstrak didapati tidak memberikan sebarang kesan secara signifikan dalam 
menurunkan aras glukosa darah tikus normal. Manakala, dalam kajian lain mengenai 
kesan antihiperglisemik yang mana tikus  yang digunakapakai telah diaruh menjadi 
diabetik dengan memberikan suntikan streptozotocin sebanyak 50 mg/ kg berat tikus. 
Pengambilan ekstrak air P. bleo telah didapati memberikan kesan signifikan dalam 
menurunkan aras glukosa darah tikus aruhan diabetik tersebut seawal 6 hari selepas 
rawatan bermula. Oleh itu, ekstrak air P. bleo telah dipilih sebagai ekstrak paling 
aktif dan difraksikan menggunakan teknik pelarut-pelarutmenjadi fraksi etil asetat, n-
butanol dan air. Kesan antihiperglisemik fraksi-fraksi ini telah diuji pada tikus 
aruhan diabetik yang mana pengambilan fraksi air P. bleo telah didapati memberikan 
xxii 
 
kesan signifikan bagi menurunkan aras glukosa darah. Kajian ini juga mendapati 
bahawa ekstrak air dan fraksi air P. bleo juga telah memberikan kesan signifikan 
dalam menurunkan aras glukosa darah, lipid berketumpatan rendah (LDL), 
trigliserida (TG) dan jumlah kolestrol (TC), mengurangkan kesan penurunan berat 
badan dan juga memberikan kesan signifikan dalam meningkatkan kadar insulin 
dalam darah. Mekanisma berkaitan kesan tersebut juga telah diuji dan didapati 
bahawa fraksi air P. bleo menujukkan kesan yang lebih menonjol berbanding ekstrak 
air P. bleo dimana ia mampu merencatkan kesan enzim α-amylase secara sederhana 
dan merencatkan kesan enzim α-glucosidase secara aktif. Dalam ujian antioksidan 
secara in vitro, ekstrak air dan fraksi air P.bleo menunjukkan kesan antioksidan yang 
sangat lemah dengan kesan lebih menonjol ke arah ujian β-karotene. Selanjutnya, 
analisis sektrum LCMS (Kromatografi Cecair Berprestasi Tinggi Spektroskopi 
Jisim) bagi fraksi air P. bleo telah mendapati tiga puncak utama, iaitu N, N- 
diethylglycine, N-stearoylvaline dan paraxanthine. Secara keseluruhannya, P. bleo 
memberikan kesan antihyperglysemik dengan merangsang perembesan insulin dan 
dengan merencatkan kesan enzim α-amylase dan α-glucosidase. Berdasarkan 
kesemua hasil kajian ini menunjukkan  bahawa pokok ini berpotensi untuk dijadikan 
bahan kajian dengan lebih mendalam bagi mengetahui mekanisma yang terbabit bagi 
kesan antihyperglysemik tersebut. 
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PHYTOCHEMICAL AND ANTIDIABETIC STUDIES OF PERESKIA BLEO 
EXTRACTS 
 
 
ABSTRACT 
  
This present study was done to evaluate the antidiabetic activities and the 
underlying mechanism associated to the observed bioactivity of Pereskia bleo leaf 
extracts. Pereskia bleo which belongs to the family Cactacae is a well-known 
traditional remedy in Malaysia for the treatment of diabetes, cancer, high blood 
pressure and diseases associated with rheumatism and inflammation. However, the 
scientific information on the usefulness in the medicinal importance of this plant 
extracts is still lacking, especially on the antidiabetic properties. Four different 
extracts of differing degrees of polarity of P. bleo leaf are selected namely 
petroleum-ether extract, chloroform extract, methanol extract and aqueous extract 
respectively. In the hypoglycaemic test and intraperitoneal glucose tolerance test 
(IPGTT), all extracts were found to be insignificant in lowering glucose level in 
blood compared to the control group. In antihyperglycaemic test, the diabetic type 2 
was induced by injecting 50 mg/kg of STZ in Sprague Dawley rats. The 
administration of P. bleo aqueous extract was found to be significant (p<0.05) in 
lowering glucose level as early as day 6 compared to negative control. Hence, P. 
bleo aqueous extract was chosen as the most active extract and was further 
fractionated using solvent-solvent extraction into ethyl acetate, butanol and aqueous 
fractions. These fractions were then being determined for the antihyperglycaemic 
properties in STZ-induced diabetic rats and the administration of P. bleo aqueous 
fraction was found to be the most potent fraction in lowering the blood glucose level. 
xxiv 
 
Our finding also reveals that P. bleo aqueous extract and its aqueous fraction also 
exhibited significant decrease in the glucose level, low density lipid (LDL), 
triglyceride (TG) and total cholesterol (TC), significant lowering effect in the 
decreasing percentage of the body weight and significant increase in plasma insulin 
level compared to diabetic control. The mechanism underlying observed antidiabetic 
activity was carried out in vitro and the result indicates that P. bleo aqueous fraction 
had demonstrated a more potent inhibitory agent compared to aqueous extract as it 
possessed a mild α-amylase inhibitory and strong α-glucosidase inhibitory properties 
respectively. In in vitro antioxidant studies, P. bleo aqueous extract and aqueous 
fraction exhibited weak antioxidant activity with the preferences towards β-carotene 
bleaching activity. Further LCMS analysis showed that the major peaks identified in 
most antidiabetic bioactive fraction, P. bleo aqueous fraction were N, N- 
diethylglycine, N-stearoylvaline and paraxanthine. Overall, P. bleo extracts exhibited 
potent antihyperglycaemic property by stimulating the insulin secretion and 
inhibiting α-amylase and α-glucosidase activities. All these findings showed the 
plant extract potentials for further in-depth mechanism study associated with 
observed antidiabetic properties. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction 
1.1.1 Diabetes 
Diabetes mellitus which is a hyperglycaemic condition characterized by high 
glucose level is a chronic endocrine syndrome associated with abnormality of 
glucose metabolism, leading to the high triglyceride and lipoprotein levels (Erciyas 
et al., 2004). This disease is caused by a loss of glucose homeostasis mainly either 
due to the defects of insulin secretion or the insensitiveness of insulin towards target 
organs, or both (Maiti et al., 2004; Alarcon-Aguilara et al., 1998). In chronic 
condition it leads to a long term dysfunction, damage or even failure of several 
organs in patients, mainly the eyes, nerves, kidney, heart and blood vessels 
(Poongothai et al., 2011). However this endemic condition has always been 
underestimated as the underlying cause of death and no proper attention has been 
given (Fuller et al, 1983). 
 
1.1.2 Diabetes statistics 
Diabetes mellitus is now being considered as one of the world’s five leading 
causes of death. In 2010, there were about 285 million people around the world 
suffering from diabetes and it is increasing throughout the years especially in rural 
population (Shaw et al., 2010).  Even Malaysia today had been known as diabetic 
capital, where more than 8.2% of its population as diabetic sufferer (Rugayah, 1997). 
There is an estimated statistics by World Health Organization (WHO) that by 2035, 
about 592 million of world’s population will suffer from this deadly disease 
especially from low and middle income class populations (International Diabetes 
Federation Atlas, 2013).  
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1.1.3 Type of diabetes 
The National Diabetes Data Group of the National Institute of Health of 
Bethesda, Maryland, USA had classified diabetes into 5 types (National Diabetes 
Data Group, 1979). Type 1 diabetes is usually known as insulin-dependent diabetes 
mellitus (IDDM). This type of diabetes is associated with the increase and decrease 
frequency of histocompatibility antigens (HLA). This type of diabetes usually can 
occur at any age, including juvenile. Treatment for this type of diabetic including the 
administration of insulin which usually be taken by mean of injection or inhalation 
(Widmaier, 2013).  
 
Type 2 diabetes is the noninsulin-dependent diabetes mellitus (NIDDM). This type 
of diabetes is very common worldwide cover up at least 90% of the diabetic statistics 
(Widmaier, 2013). This type of diabetes can be divided into two subclasses, the 
obese NIDDM and the nonobese NIDDM. Type 2 diabetes usually occurs in elderly 
stage of life. The therapy for this type of diabetes usually involved some 
combination of insulin or drug which can increase the insulin sensitiveness 
(Widmaier, 2013).  
 
Other types of diabetes are type 3, type 4 and type 5 which are rare in population. 
The diabetes caused by other conditions is being classified as type 3 diabetes 
mellitus. It is diabetes associated with certain condition and syndromes which can be 
divided to known or suspected relationships. Type 4 diabetes is the gestational 
diabetes which is restricted to pregnant women with glucose intolerance developed 
or discovered during the pregnancy. The last type of diabetes is type 5, where the 
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individuals have plasma glucose levels that are at intermediate level between being 
diabetic and normal. This condition is being referred as impaired glucose tolerance.  
 
1.1.4 Causes of diabetes 
The main factor leading to diabetes is based on the insulin, whether insulin 
resistance, insulin action or both (Maiti et al., 2004; Alarcon-Aguilara et al., 1998). 
In type 1 diabetes mellitus, it is due to the insulin deficiency which happen because 
of the total or near-total destruction of pancreatic β-cells, occurs as the auto-immune 
response of body’s white blood cells (Widmaier, 2013). The therapy involved insulin 
intake via parenteral injection as the body failed to produce by its own. Meanwhile, 
in type 2 diabetes mellitus, the diabetic condition occurs as the inadequate secretion 
of insulin which may be due to the defects or compromised function of β-cells, and 
thus failed to normalise the plasma glucose concentration (American Diabetes 
Association, 2010). Besides, the other factor leading to the type 2 diabetes mellitus is 
due to the target organs or cells which become hyporesponsive towards the insulin, 
or being known as insulin resistance (Widmaier, 2013). It is defined as the impaired 
ability of the insulin to control the glucose in the target organs (Oberley, 1988). 
These conditions, the insulin secretion impaired and insulin action defects usually 
coexist in one person (American Diabetes Association, 2010).   
 
1.1.5 Diabetic induced in laboratory 
Although there are about 5 types of diabetes occur, only type 1 and type 2 
diabetes (IDDM and NIDDM respectively) were common in scientific research on 
natural products. Experimental diabetes had been induced in laboratory research on 
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animal model through chemicals which selectively destroy the β-cells in pancreas, 
thus reducing the total insulin secretion. Alloxan and streptozotocin are the most 
common chemicals used to evoke such diabetes condition.  
 
1.1.5(a) Mechanism of action of alloxan 
Alloxan or 2,4,5,6-tetraoxypyrimidine was known to exhibit the diabetogenic 
properties and commonly used in laboratory research to induce type 1 diabetes 
mellitus or insulin de pendent diabetes mellitus (IDDM) in animal model (Dunn et 
al., 1943). Alloxan were administered to animal through parenterally either by 
intravenous, subcutaneous or intraperitoneal injection (Szkudelski, 2001). The 
alloxan were taken up by insulin-secreting cell rapidly and formed a reactive oxygen 
species in β-cells (Heikkila et al., 1976). The alloxan will get reduced prior to the 
reactive oxygen species formation and leading to the formation of disulphide bond 
and inactivation of enzymes (Szkudelski, 2001). The diabetogenic action of alloxan 
on β-cells in pancreas were either by oxidation of essential -SH groups, free radical 
formation, glucokinase inhibition or intracellular calcium homeostasis disturbances 
(Szkudelski, 2001). However, the alloxan action is not so selective and the range of 
diabetogenic dose is quite narrow making alloxan use to induce diabetic in animal 
model is a difficult dosage optimization task.  
1.1.5(b) Mechanism of action of streptozotocin 
Streptozotocin (STZ) or 2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-
glucopyranose is synthesised by Streptomycetes achromogenes. STZ administration 
dose for diabetogenic was not as narrow as alloxan and was widely used in 
laboratory research to induced both type 1 (insulin-dependent) and type 2 (non-
insulin-dependent) diabetes mellitus (IDDM and NIDDM respectively) in animal 
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model (Szkudelski, 2001). STZ will destroy the β-cells and inhibits its insulin 
secretion through its alkylation potency of DNA (Lenzen, 2008; Delaney et al., 
1995; Elsner et al., 2000). The STZ is more selective on the β-cells specificity 
compared to alloxan, making it as the primary chemical-inducing diabetic agent in 
animal model (Lenzen, 2008).  
 
1.1.6 Treatment of diabetes 
1.1.6(a) Oral hypoglycaemic drug 
There are several classes of oral antidiabetic drug, which had been classified 
based on their effects, mechanism of action and adverse reaction on diabetes 
condition which are sulfonylureas, biguanides, alpha-glucosidase inhibitors, 
meglitinides, thiazolidinediones and many more. The main goals of clinical therapy 
on diabetic patients are to achieve better glucose level and to prevent the long term 
diabetic complication (Turner et al., 1999). In comparing to the newer agents such as 
alpha-glucosidase inhibitors, meglitinides, and thiazolidinediones, the older agents 
such as sulfonylureas and biguanides are cheaper and exhibited the same therapeutic 
values in managing the glycaemic level (Bolen et al., 2007).These clinical drugs 
were usually being prescribed alone as monotherapy or by combination of two or 
more depending on the diabetes condition (Emilien et al., 1999). Majority of the 
diabetic patients needs multiple therapies to maintain their glycaemic levels for long 
term (Turner et al., 1999).  
 
The sulfonylureas improves the glucose management by stimulating the insulin 
secretion (Pfeifer et al., 1980).  Glibenclamide is a potent second generation 
sulfonylurea drug that improves glucose control by stimulating the insulin secretion 
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and action (Luzi & Pozza, 1997). It is also one of commercial drugs used to treat 
diabetes. The principle of action in glibenclamide is proven to be on the β-cells of 
the islets of Langerhans in pancreas, stimulating insulin secretion and action and thus 
reducing the plasma glucose concentration. Adverse reaction of clinical treatment of 
this drug and other sulphonylurea derivatives however showed cardiovascular events 
in patients with non-insulin dependent diabetes mellitus (Smits, et al., 1995). 
 
Metformin (1.1-dimethylbiguanide hydrochloride), a commercial hypoglycaemic 
drug for the treatment of diabetes is the only drug that belongs to the biguanide class, 
which is the guanidine derivatives. Metformin was first extracted from Galega 
officinalis and it is the first-line oral antidiabetic drug for the treatment of type 2 
diabetes. Its mechanism of action is through promoting glucose uptake by tissues 
(via glucose transporters), especially those of skeletal muscles and inhibits hepatic 
gluconeogenesis. Activation of AMPK (AMP-activated protein kinase) appears to be 
the main mechanism of its antihyperglycaemic action, but metformin also acts on 
small-intestine glucose metabolism (Bouchoucha et al, 2011).  
 
The other class of oral antidiabetic drug is the α-glucosidase inhibitors. This class of 
drug functions directly by inhibiting those enzymes responsible for the glucose 
metabolism and thus delay the digestion of carbohydrate, prolong the time needed 
for the digestion and thus will reduce the glucose absorption rate that will aid in 
preventing the postprandial glucose rise in blood (Rhabasa-Lhoret & Chiason, 2004). 
The drugs which fall under this class include the acarbose, miglitol and voglibose. 
The  long term and continuous intake of this class of drug should be controlled and 
limited as it produce adverse reaction such as abdominal cramps, diarrhoea, 
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flatulence, vomiting and even some serious incidence like acute hepatitis and renal 
tumors (Hanefeld, 1998; Diaz-Gutierrez et al., 1998). This adverse reaction is the 
result of the bacteria fermentation of undigested carbohydrate in colon (Bischoff, 
1994).  
 
1.1.6(b) Insulin 
Insulin is a key regulating hormones that control the blood glucose 
concentration in body. In normal condition, β-cells in pancreas will secrete the 
insulin. However, in certain condition, as diabetes, the body failed to secrete the 
insulin, or secrete inadequately to lower the glucose level to normal level. Hence, for 
some type of diabetes, especially for type 1 diabetes mellitus, the insulin injection is 
needed in managing the diabetes condition (Widmaier, 2013). Insulin secretion and 
action are based on the plasma glucose concentration (Widmaier, 2013).Insulin acts 
in body by enhancing the glucose transport through the cell membrane and 
facilitating the glucose metabolism, and thus will lower the glucose level in blood 
(Dimitriadis et al., 2011).This hormone affects majorly on muscle and adipose tissue 
by aiding in carbohydrate metabolism, lipid metabolism and protein metabolism. In 
carbohydrate metabolism, the insulin increases the transportation rate of glucose 
through the cell membrane, increases the glycolysis (glucose breakdown to pyruvate 
or lactate) rate by stimulating the hexokinase and 6-phosphofructokinase activity, 
increases the glycogen synthesis rate and inhibits the glycogenolysis (glycogen 
breakdown to glucose) and gluconeogenesis (formation of glucose from pyruvate, 
lactate, glycerol or amino acids) rate (Dimitriadis et al., 2011). Upon lipid intake, the 
insulin acts by decreasing the lipolysis and fatty acid oxidation rate, stimulates the 
synthesis of fatty acid and triacylgylcerol and increases triacylglycerides uptake by 
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adipose tissue and muscle (Dimitriadis et al., 2011). Insulin which also acts on 
protein metabolism also increases the amino acids transport rate, increases the 
protein synthesis rate and decrease the protein degradation rate in muscle 
(Dimitriadis et al., 2011). The overall insulin mechanism is an effective therapy in 
managing the glucose level in blood especially after carbohydrate consumption, 
since the increasing postprandial blood glucose holds more risk to cardiovascular 
disease as compared to fasting glucose level (Narkhede et al., 2011).  
 
1.1.6(c) Diet control 
Beside the antidiabetic drugs, the diabetic patients are highly recommended 
to control their diet in order to achieve a well maintained glycaemic index to prevent 
the associated risk. Some of the diabetic sufferer can maintain their blood glucose 
level just by controlling the diet alone as a short term therapy.  The intensive diet 
program as early as the diabetes is diagnosed is likely to improve glycaemic control 
and thus manage the blood glucose level (Andrews et al., 2011). The diet controlled 
program which includes eating a balanced diet, taking appropriate snack to prevent 
hypoglycaemia, avoiding high glucose intake, maintaining food portion and eating 
time, avoiding high saturated fat food intake and supplementation with appropriate 
dietary fibres may be beneficial in aiding the diabetic management (Chase, 1979).  
1.1.6(d) Exercise 
Exercise has the key important role in managing diabetes. Together with the 
clinical drug, a controlled diet and an appropriate physical activity program can be a 
better therapy to improve glycaemic control and reduce the cardiovascular risk 
associated with diabetic (American Diabetes Association, 2002). This 
recommendation is proposed as the benefits of exercise may underweight the 
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associated risk. The physical activity may improves body fitness and thus affect the 
metabolic response. Upon frequent endurance exercise, the insulin sensitiveness may 
increase as it increases the total number of plasma membrane glucose transporter and 
hence aids in diabetic management (Widmaier, 2013). Therefore, self-monitoring of 
blood glucose level is highly recommended to diabetes patients who embark on this 
exercise program as to prevent the hypoglycaemic condition which may be fatal 
(American Diabetes Association, 2002).  
 
1.1.7 Natural products as the alternative source for human diseases treatment 
Natural products have been playing a dominant role in the discovery of leads 
for the development of drugs for the treatment of human diseases. An encouraging 
report from world ethnobotanical information about medicinal plants states that as 
many as 800 plants are being used in the control of diabetes mellitus to date 
(Alarcon-Aguilara et al., 1998). Many of the currently available drugs have been 
derived directly or indirectly from plant. Indeed, the vast majority of the existing 
antidiabetic drugs are based on natural products such as metformin which originates 
from Galega officinalis, and this fact anticipates that new more effective leads may 
certainly emerge from the tropical plant sources, since biological chemodiversity 
continues to be an important source of molecular templates in the search for new 
antidiabetic agents. Natural products are a primary source to obtain cheap and 
alternative antidiabetic drug. Moreover, the need for new safe template is needed as 
existing clinical drugs for the treatment of diabetes can produce a number of adverse 
reactions among diabetes patients.  
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1.1.8 Pereskia bleo 
Pereskia which belongs to the family Cactaceae is the only genus in this family that 
is leafy and not a desert-adapted cactus. This genus was named as an honour to a 
French botanist in 16
th
 century, Nicolas Fabre de Peiresc (Hassanbaglou et al., 2012). 
There are 17 species that are fall under the Pereskia genus with two sub groups. 
Most of them were economically unimportant and some were considered as 
troublesome to the biodiversity (Campbell, 1988). However, there are three species 
that are traditionally popular for their medicinal properties which are Pereskia 
aculeata (Miller), Pereskia grandifolia (Haw) and Pereskia bleo (Kunth). In 
Malaysia, Pereskia grandifolia and Pereskia bleo were locally known as Jarum 
Tujuh Bilah and usually cultivated as an ornamental plant. P. grandifolia and P. bleo 
can visually distinguished by the colour of their flowers which are purple coloured in 
P. grandifolia and orange-red coloured in P. bleo.  
 
1.1.9 Morphological decription of Pereskia bleo 
Pereskia bleo is a spiny shrub with lot of oval-in-shape, glossy, green in 
colour leaf (Figure 1.1 and Figure 1.2). Locally known as Jarum Tujuh Bilah (seven 
needles), this plant has a lot of spines that are usually seven in average for one spot. 
It produces visible fruits with waxy hemispherical in shape, which is green in colour 
and will turn to yellow upon ripening. The medium size orange-red coloured flower 
will bloom during late afternoon and only lasts for one day (Sim et al., 2010). This 
species prefer dry and full sun condition and can be cultivated by their stem cutting. 
The complete taxonomy classification of this species is as tabulated in Table 1.1. 
Traditionally, it was claimed to be useful in treating several diseases such as 
diabetes, rheumatism, inflammation, ulcer, gastric pain, tumor, cancer, hypertension, 
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anti-snake bite and revitalizing the body (Wahab et al., 2009; Sharf et al., 2013). The 
local folks usually consumed it as a brewed concoction or as raw leaf salad. There 
was a preliminary survey done in Kelantan that reported P. bleo leaf wide use by 
local diabetic patient for lowering the blood glucose level (Khor et al, 2013).  
 
Table 1.1: Taxonomic classification of Pereskia bleo 
Taxonomic classification 
Kingdom Plantae 
Phylum Tracheophyta 
Class Magnoliopsida 
Order Caryophyllales 
Family Cactaceae 
Genus Pereskia 
Species Pereskia bleo 
 
Figure 1.1: Pereskia bleo tree. 
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Figure 1.2: a) The leaf and flower of Pereskia bleo; b) the ripe fruit of Pereskia 
bleo; c) the spine of Pereskia bleo stem. 
 
1.1.10 Pharmacological review on Pereskia bleo 
Recently, several scientific research have been done to evaluate the potent 
bioactivity of the plant extract to justify its traditional claims.  Ahmed et al. (2014) 
demonstrated that after single oral administration of 250 mg/kg of body weight 
aqueous and ethyl acetate extracts of P. bleo significantly lowered the blood glucose 
level of alloxan induced diabetic rats approximately 24 hours following treatment. 
The study also showed that both extracts inhibited α-amylase and α-glucosidase 
activities in vitro. In an acute oral toxicity study, Sim et al. (2010a) reported that P. 
bleo could be regarded as non toxic in experimental mice with lethality dose, 
LD50>2500mg/kg. 
 
P. bleo methanol extract was found to be a strong cytotoxic agent against human 
mammary carcinoma cell, T-47D via apoptosis mechanism by the activation of 
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caspase-3 ans c-myc pathways (Tan et al., 2005). Other studies by Malek et al., 
(2008 and 2009) also found that P. bleo ethyl acetate and methanol extracts showed 
significant effect of cytotoxicity in human nasopharyngeal epidermoid carcinoma 
cell line (KB). 
 
P. bleo also exhibited potent antioxidant activity. In less polar solvent extraction 
methods, several studies also found that the P. bleo hexane extract exhibited strong 
2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenger capability and significantly 
reduced the ferric chloride in Ferric Reducing Power (FRAP) assay, while ethyl 
acetate extract of P. bleo showed significant effect in DPPH scavenging activity, in 
β-carotene bleaching assay, and in 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid) (ABTS) assay (Sim et al., 2010 (a); Sim et al., 2010 (b); Hassanbaglou et al., 
2012; Wahab et al., 2009; Bakhari et al., 2010). This plant butanol extract also was 
reported to possessed good antioxidant properties in ABTS assay (Lee et al., 2009).   
 
P. bleo also exhibited some antimicrobial and anti-noniceptive activities as reported 
by Philip et al. (2009) which found that P. bleo extracts possessed moderate 
inhibition activity against Pseudomonas aeruginosa and some gram-negative 
bacteria. In another study,  P. bleo hexane extract also showed significant effect in 
anti-noniceptive activities as in formalin-induced test, plant ethyl acetate extract 
showed lowest number of contortions in  acetic acid-induced abdominal writhing test 
while butanol extract exerted anti-noniceptive activity in the hot plate test (Wahab et 
al., 2012).  
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1.1.11 Phytochemical review of Pereskia bleo 
The chemical constituents in P. bleo had been evaluated by several studies 
associated with certain bioactivities. Earlier, Doetsch et al. (1980), showed four 
constituents of alkaloids were isolated from Pereskia plant namely 3,4-dimethyl-β-
phenethylamine, mescaline, 3-methoxytyramine and tyramine respectively. Malek et 
al. (2008; 2009) then isolated several cytotoxic components in P. bleo ethyl acetate 
fraction through bioactivity guided fractionation namely dihydroactinidiolide, 
mixture of sterol (compasterol, stigmasterol and β-sitosterol), 2,4-di-tert-
butylphenol, α-tocopherol and phytol. In another research, Wahab et al. (2012) was 
then successfully isolated three compounds namely vitexin, β-sitosterol glucoside 
and β-sitosterol from P. bleo ethyl acetate, dichloromethane and hexane extracts 
respectively and were further tested on anti-noniceptive activities.  
 
Subsequently, several quantitative phytochemical screenings were also reported. The 
P. bleo ethyl acetate extract was found to exhibit higher total contents of phenolics 
compared to other solvents extracts (Sim et al., 2010b). In other study, the catechin, 
epicathecin, quercetin and myricetin contents were identified as the major flavonoids 
in P. bleo (Hassanbaglou et al., 2012).  
 
1.2 Rationale of the study 
Diabetes mellitus has become one of the major health problems, which is 
affecting nearly 285 million of the world population (Mustaffa et al, 2011). To date, 
it has become an increasingly important cause of mortality in population of many 
countries. Moreover, the need for a new template or lead compound is now 
important as existing clinical drugs for the treatment of diabetes have been producing 
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a number of adverse reactions. For example, cardiovascular events in patients with 
non-insulin dependent diabetes mellitus are prevalent among the widely prescribed 
sulphonylurea and its derivatives(Smits et al., 1995).  
 
For decades, diabetic patients in less developed nations have relied on oral 
treatments of traditional medicines sourced by the various types of local plant extract 
(Singh et al., 2001) even though no scientific data accompanied these medicinal 
claims. Malaysia which is rich biodiversity forest is endowed with a variety of herbal 
medicines but yet, the scientific evidence is still lacking. To date, there is a need to 
investigate Pereskia bleo extract as antidiabetic agent based on the traditional 
medication, as no clear scientific data has linked the plant constituents to its 
observed antidiabetic effect as local traditional remedy. Hence, this present study 
will provide valuable data regarding medicinal properties of Malaysia herbal plant 
extract. Identification of new local medicinal plant bioactives and their mechanism 
of action will produce new lead compounds or template as effective, highly 
therapeutic new agents for pharmaceutical industry. This may also contribute to 
production of potential nutraceutical products in prevention of the chronic disease 
and to combat against diabetes. All Pereskia bleo extract baseline data together with 
findings on a fully elucidated mechanism of action will also contribute to a complete 
government Herbal Monograph. 
 
Pereskia bleo, a green leafy cactus with distinctive orange-red flower, has been 
introduced as an ornamental plant due to its beautiful flowers. This plant is a tropical 
adapted plant, it grows well in Malaysia climates and can be cultivated extensively in 
this country.  
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1.3 Hypothesis of the study 
A survey in Kelantan reported that P. bleo leaf was widely used to treat diabetes 
mellitus (Khor et al., 2013). Therefore, it is hypothesized that P. bleo leaf extract 
could lower blood glucose level of diabetic rats with various mechanism of action 
contributed by active compounds in the leaf.   
 
1.4 Objectives of the study 
The objectives of this present study are: 
 To determine the antidiabetic effect of Pereskia bleo leaf extracts. 
 To extract P. bleo using solvents of increasing polarity (i.e petroleum 
ether, chloroform, methanol and aqueous) and investigate the blood 
glucose lowering activity of the extracts in normal rats, glucose-loaded 
rats and streptozotocin induced diabetic rats.  
 To fractionate the most active extract into different fractions (i.e. from 
aqueous extract into ethyl acetate, n-butanol and aqueous fractions) and 
determine the most bioactive fraction associated with the evaluated 
antidiabetic activity. 
 To determine the blood glucose lowering mechanism and antioxidant 
activity of the most bioactive extract and fraction. 
 To identify the potential antidiabetic bioactive compound(s) in the most 
active fraction.  
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CHAPTER 2 : THE BIOASSAY GUIDED EVALUATION ON GLUCOSE  
LOWERING EFFECT OF PERESKIA BLEO EXTRACTS AND FRACTIONS 
 
2.1 Introduction 
Diabetes mellitus, a serious endocrine syndrome is one of the five world 
leading cause of death (Alarcon-Aguilara et al., 1998; Chakraborty & Das, 2010). It 
is a metabolic disease which is characterized by a decrease in insulin production and 
insulin insensitivity of target organ or both (Edwin et al., 2004). Diabetes condition 
is highly associated with defect of glucose metabolism which in turn increases the 
triglyceride and lipoprotein levels (Erciyas et al., 2004). For clinical treatment, a 
combination of both oral hypoglycaemic and insulin administrations always been 
used. However, the adverse reaction observed such as coma and liver and kidney 
failures have always been observed following treatment (Rajesh et al., 2010).  
 
There are many methods to screen for antidiabetic properties in laboratory and one 
of them involved using chemical agents to induce animal to create a diabetic 
condition (Nain et al., 2012). Streptozotocin (STZ) is widely used to induce both 
insulin-dependent and non-insulin-dependent diabetes mellitus (Szkudelski, 2001). 
STZ acts by selectively destroying the β-cells in pancreas and thus decreasing the 
insulin production leading to a diabetic condition (Nain et al., 2012).  
World ethnobotanical information reported that a total of 800 plants have been 
associated with diabetes control but very few have been scientifically studied 
(Alarcon-Aguilara et al., 1998). There is a much needed effort for new antidiabetic 
drugs as the existing clinical oral synthetic agents seems to produce debilitating 
adverse reaction. Nowadays, researchers worldwide are also approaching natural 
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product as an alternative to drugs that may produce equal or better efficacy, but less 
or no side effects and relatively low in cost when compared to the established 
clinical therapy (Nanu et al., 2008).  
   
Hence, in this chapter the antidiabetic properties of P. bleo extracts at their varying 
polarity will be evaluated in in vivo studies on normal rats and diabetic induced rats. 
The hypoglycaemic properties and glucose tolerance ability of plants extracts will be 
determined in normoglycaemic rats respectively. Then, the antihyperglycaemic 
properties will be further evaluated on streptozotocin induced diabetic rats for 12 
days. The most active extract will be further fractionated and further tested for the 
antihyperglycaemic properties in diabetic rats. Dose response relationship of the 
most active fraction will then be tested on the antihyperglycaemic properties. Lastly, 
the effect of the most active extract and fraction will be further evaluated on the 
blood glucose level, insulin level, lipid profile and the body weight of the diabetic 
rats. This is a bioactivity guided fractionation of the plant extracts where further 
investigation work of the most potent extract and fraction of the plant extracts will be 
perform using in vivo models.  
2.2 Materials and Methods  
2.2.1 Chemical 
Streptozotocin was purchased from the Sigma-Aldrich (USA) company. 
Glibenclamide and metformin (standard drugs) used were from Hovid Bhd. Kit for 
insulin assay namely Ultra Sensitive Rat Insulin ELISA Kit from Crystal Chem Inc. 
(USA). All other commercial reagents and solvents used were of analytical grade. 
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2.2.2 Plant sample 
The leaves of P. bleo were collected from one source at Kubang Semang, 
Bukit Mertajam, Penang and a voucher has been authenticated by a plant expert, Dr. 
Rahmad Zakaria and deposited at the Herbarium Unit of the School of Biological 
Sciences, Universiti Sains Malaysia (USM/Herbarium/11609).   
 
2.2.3 Experimental animal 
Healthy male Sprague Dawley (SD) rats weighing between 200 to 250 g 
obtained from Animal Research and Service Centre (ARASC), Universiti Sains 
Malaysia (USM), Penang, Malaysia were used in this study. All the animals were 
kept in Animal Transit Room, School of Pharmaceutical Sciences, USM. They were 
allowed to access to standard food pellet (Gold Coin Sdn. BHD., Malaysia) and tap 
water, ad libitum. The procedures for this study have been approved by the Animal 
Ethics Committee of USM, Penang with the number of Animal Ethics Approval is 
USM/ Animal Ethics Approval/ 2013/ (87) (463) (attached as Appendix 2.1 and 2.2).  
2.2.4 The bioassay guided evaluation of antidiabetic effect of P. bleo extracts 
2.2.4(a) Plant material collection and preparation of extracts 
The fresh leaves were washed and dried for several days in 40°C temperature 
control oven. The dried leaves were milled into powder form using Wiley 
Laboratory Mill apparatus and then extracted by with petroleum-ether using 
maceration technique at room temperature for 24 hours. The residues were then re-
extracted by chloroform, methanol and water serially using the same technique. Each 
organic extracts were then filtered using Whatmann no 1 filter paper and 
concentrated on rotary evaporator (Eyela) in 40°C. Aqueous extracts was evaporated 
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off at 60°C. The aqueous extract was further dried out completely using freeze drier 
machine (Labconco) to yield dry powder form. All the four extracts were stored in 
freezer until it is ready to be used.  
 
2.2.4(b) Hypoglycaemic test in normal rats 
A group of 36 overnight fasted Sprague Dawley rats were equally divided 
into six groups.  
Group One (n=6) served as negative control and received 10% tween 20 (10 ml/kg 
body weight (b.w))  
Group Two (n=6) served as positive control and received glibenclamide (10 mg/kg 
b.w) 
Group Three (n=6) received petroleum-ether extract of P. bleo (1000 mg/kg1000 
mg/kg b.w)  
Group Four (n=6) received chloroform extract of P. bleo (1000 mg/kg1000 mg/kg 
b.w)  
Group Five (n=6) received methanol extract of P. bleo (1000 mg/kg1000 mg/kg b.w)  
Group Six (n=6) received aqueous extract of P. bleo (1000 mg/kg1000 mg/kg b.w)  
The treatments were given orally. Blood samples were withdrawn from tail vein at 0, 
1, 2, 3, 5 and 7 hours following treatment and blood glucose levels were determined 
using glucose meter (ACCU-CHEK
®
 Performa).  
 
2.2.4(c) Intra peritoneal glucose tolerance test (IPGTT) 
A group of 36 male Sprague Dawley rats were equally divided into six 
groups and were fasted overnight.  
